Form 8-K · Current Report · Filed 2025-10-06
Gilead Sciences Settles Patent Litigation with Generic Manufacturers
On October 6, 2025, Gilead Sciences, Inc. announced settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigation over generic versions of Biktarvy. The settlements delay generic entry until April 1, 2036, in the United States. Gilead also furnished an interactive data file as part of this filing.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0000882095-25-000041
- CIK
- 0000882095
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$112.69
Next session
+3.6%
Since filing
+15.5%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.